CIK 0001590750 · Large accelerated filer
Viridian Therapeutics, Inc.\DE
Sign in to watch- Ticker
- VRDN
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 471187261
- Phone
- 617.272.4600
- Business address
- 221 CRESCENT STREET, SUITE 103A, WALTHAM, MA, 02453
- Former names
- MIRAGEN THERAPEUTICS, INC., SIGNAL GENETICS, INC., SIGNAL GENETICS LLC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $348,194
- in 1 filing
Net −$348,194. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-03-03 | Harmon Seth Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +150,407 | 150,407 | ||
| 2025-03-03 | Harmon Seth Chief Financial Officer | Grant or award · Restricted Stock Units | +25,068 | 25,068 | ||
| 2024-09-27 | Beetham Thomas W. Chief Operating Officer | Purchase | +5,000 | $23.41 | $117K | 6,000 |
| 2024-09-27 | Mahoney Stephen F. President and CEO | Purchase | +21,400 | $23.33 | $499K | 21,400 |
| 2024-09-13 | Fairmount Funds Management LLC Director | Purchase | +1,600,000 | $18.75 | $30.0M | 3,445,813 |
| 2024-06-26 | Gheuens Sarah Director | Grant or award · Stock Option (Right to Buy) | +21,000 | 21,000 | ||
| 2024-06-26 | Harwin Peter Evan Director | Grant or award · Stock Option (Right to Buy) | +21,000 | 21,000 | ||
| 2024-06-26 | Kiselak Tomas Director | Grant or award · Stock Option (Right to Buy) | +21,000 | 21,000 | ||
| 2024-06-26 | Morris Arlene Director | Grant or award · Stock Option (Right to Buy) | +21,000 | 21,000 | ||
| 2024-06-26 | Moses Jennifer K. Director | Grant or award · Stock Option (Right to Buy) | +21,000 | 21,000 | ||
| 2024-03-28 | Fairmount Funds Management LLC Director | Other disposition | −5,859 | 0 | ||
| 2024-03-28 | Fairmount Funds Management LLC Director | Other acquisition | +5,859 | 1,845,813 | ||
| 2024-03-28 | Fairmount Funds Management LLC Director | Other disposition · Series A Non-Voting Convertible Preferred Stock | −21,999 | 0 | ||
| 2024-03-28 | Fairmount Funds Management LLC Director | Other acquisition · Series A Non-Voting Convertible Preferred Stock | +21,999 | 133,191 | ||
| 2024-02-12 | Tousignant Jennifer Chief Legal Officer | Grant or award · Stock Option (Right to Buy) | +290,000 | 290,000 | ||
| 2024-02-05 | Ciulla Thomas Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +50,000 | 50,000 | ||
| 2024-01-22 | Fairmount Funds Management LLC Director | Purchase | +476,190 | $21.00 | $10.0M | 1,839,954 |
| 2023-11-10 | Harmon Seth See Remarks | Grant or award · Stock Option (Right to Buy) | +270,000 | 270,000 | ||
| 2023-10-30 | Fairmount Funds Management LLC Director | Grant or award · Series B Non-Voting Convertible Preferred Stock | +48,463 | $825.37 | $40.0M | 48,463 |
| 2023-10-30 | Beetham Thomas W. Chief Operating Officer | Grant or award · Stock Option (Right to Buy) | +474,400 | 474,400 |
Page 4 of 10 · 182 trades